Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC By Ogkologos - July 9, 2025 524 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR When Cancer Spreads to Bone, A Single Dose of Radiation Therapy... May 21, 2019 Drug Regimen Boosts Survival of People with Advanced Colorectal Cancer May 24, 2023 Prize winning early detection research October 7, 2021 NCI Initiative Aims to Boost CAR T-Cell Therapy Clinical Trials April 23, 2020 Load more HOT NEWS Researchers May Be Able to Predict Breast Cancer Metastasis by Changes... Becoming My Own Advocate While Living With a Rare Cancer: A... High-Deductible Health Plans Linked to Delayed Diagnosis and Treatment of Breast... Her Cancer Surgery Was Postponed Due To The COVID-19 Pandemic —...
